Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.53 |
| ▸ | KDR | P35968 | 3/20 | 0.53 |
| ▸ | CDK2 | P24941 | 4/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.34 |
| ▸ | WEE1 | P30291 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4430517 | 0.98 | AURKA (0.51) | AURKAKDRCDK2PARP1AURKB | |
| Hydrochloric Acid SCHEMBL4436439 | 0.98 | AURKA (0.51) | AURKAKDRCDK2PARP1AURKB | |
| SCHEMBL15416821 | 0.78 | KDR (0.47) | AURKAKDRCDK2PARP1AURKB | |
| SCHEMBL10702785 | 0.74 | AURKA (0.42) | AURKAKDRMEN1KMT2AADRA1A | |
| SCHEMBL6706494 | 0.74 | AURKA (0.54) | AURKAKDRCDK2MEN1KMT2A | |
| SCHEMBL30775288 | 0.72 | KDR (0.61) | AURKAKDRPARP1LTKCSNK1A1 | |
| SCHEMBL9806074 | 0.72 | IDO1 (0.40) | AURKAKDRCDK2AURKBDAO | |
| SCHEMBL31408898 | 0.72 | AURKA (0.42) | AURKAKDRCDK2AURKBDAO | |
| SCHEMBL630634 | 0.71 | HDAC6 (0.41) | AURKAKDRCDK2PARP1AURKB | |
| SCHEMBL6425215 | 0.70 | AURKA (0.43) | AURKAKDRCDK2PARP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025120200-A1 | NEW ANTI-INFECTIVE TRICYCLIC SPIROLACTAMS COMPOUNDS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2025-06-12 | — | — | WO | claimed |
| CN-119350239-A | 5-Quinoline penta-2, 4-diene amide derivative and preparation method and application thereof | 常熟理工学院 | 2025-01-24 | — | — | CN | claimed |
| CN-114891011-B | Preparation method of medical intermediate 2-amino-tetrahydropyran [3,2-c ] quinoline-5-one derivative | 南京苏亦欣医药科技有限公司 | 2025-01-17 | — | — | CN | claimed |
| CN-118530732-A | Isothiocyanate liquid crystal material and application thereof | 华为技术有限公司 | 2024-08-23 | — | — | CN | claimed |
| CN-118530733-A | Heterocyclic liquid crystal material and application thereof | 华为技术有限公司 | 2024-08-23 | — | — | CN | claimed |
| EP-4392425-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF | Impact Therapeutics (Shanghai), Inc. (CN) | 2024-07-03 | — | — | EP | claimed |
| WO-2023025307-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2023-03-02 | — | — | WO | claimed |
| EP-2125813-A2 | COMPOUNDS | Glaxo Group Limited (GB) | 2009-12-02 | — | — | EP | claimed |
| CN-100475207-C | 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2009-04-08 | — | — | CN | claimed |
| WO-2008116815-A2 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | claimed |
| EP-1692138-A1 | PYRANO-QUINOLINES, PYRANO-QUINOLINONES, COMBINATIONS THEREOF, PHOTOCHROMIC COMPOSITIONS AND ARTICLES | TRANSITIONS OPTICAL, INC. (US) | 2006-08-23 | — | — | EP | claimed |
| CN-1655788-A | 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2005-08-17 | — | — | CN | claimed |
| WO-2005061514-A1 | PYRANO-QUINOLINES, PYRANO-QUINOLINONES, COMBINATIONS THEREOF, PHOTOCHROMIC COMPOSITIONS AND ARTICLES | TRANSITIONS OPTICAL, INC. (US) | 2005-07-07 | — | — | WO | claimed |
| CN-1093860-C | Pyridazino [4, 5-b ] quinoline 5-oxide derivatives, their preparation and their use as glycine antagonists | MERZ & CO GMBH & CO (DE) | 2002-11-06 | — | — | CN | claimed |
| EP-1194429-A1 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-10 | — | — | EP | claimed |
| WO-2000078768-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | claimed |
| EP-1040097-A1 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2000-10-04 | — | — | EP | claimed |
| CN-1228778-A | Pyridazino [4,5-b]-quinoline 5-oxide derivatives, their preparation and their use as glycine antagonists | MERZ & CO GMBH & CO (DE) | 1999-09-15 | — | — | CN | claimed |
| WO-1999031059-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 1999-06-24 | — | — | WO | claimed |
| WO-2025120200-A1 | NEW ANTI-INFECTIVE TRICYCLIC SPIROLACTAMS COMPOUNDS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2025-06-12 | — | — | WO | disclosed |
| EP-4543437-A1 | 3-?HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119569751-A | Compound, liquid crystal composition and application thereof | 华为技术有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119350239-A | 5-Quinoline penta-2, 4-diene amide derivative and preparation method and application thereof | 常熟理工学院 | 2025-01-24 | — | — | CN | disclosed |
| CN-114891011-B | Preparation method of medical intermediate 2-amino-tetrahydropyran [3,2-c ] quinoline-5-one derivative | 南京苏亦欣医药科技有限公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-119176798-A | Dihydropyrimidinone-coumarin derivative and preparation method thereof | 宜春学院 | 2024-12-24 | — | — | CN | disclosed |
| CN-118530732-A | Isothiocyanate liquid crystal material and application thereof | 华为技术有限公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-118530733-A | Heterocyclic liquid crystal material and application thereof | 华为技术有限公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-118451068-A | Tri-fused ring derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-08-06 | — | — | CN | disclosed |
| EP-4392425-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF | Impact Therapeutics (Shanghai), Inc. (CN) | 2024-07-03 | — | — | EP | disclosed |
| CN-113677680-B | EGFR inhibitor, composition and application thereof | 贝达药业股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| EP-4326726-A2 | METHODS, KITS AND COMPOSITIONS FOR REDUCING CHROMOSOMAL INSTABILITY IN CANCER CELLS | Baruch S. Blumberg Institute (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2023250480-A1 | 3-βHSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2023-12-28 | — | — | WO | disclosed |
| CN-117295733-A | Immunomodulator and immunomodulator conjugates | 明尼苏达大学董事会 | 2023-12-26 | — | — | CN | disclosed |
| WO-2023107371-A1 | SOLID FORMS OF RESIQUIMOD AND FORMULATIONS THEREOF | SURGE Therapeutics, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023025307-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2023-03-02 | — | — | WO | disclosed |
| CN-115087486-A | Substituted bicyclic and tricyclic ureas and amides, analogs thereof, and methods of use thereof | 爱彼特生物制药公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-114891011-A | Preparation method of medical intermediate 2-amino-tetrahydropyrano [3, 2-c ] quinoline-5-ketone derivative | 南京苏亦欣医药科技有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20220133740-A1 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | Frequency Therapeutics, Inc. (US) | 2022-05-05 | — | — | US | disclosed |
| CN-109071535-B | NLRP3 modulators | 先天肿瘤免疫公司 | 2021-10-08 | — | — | CN | disclosed |
| EP-3887478-A1 | COMPOUNDS FOR ELECTRONIC DEVICES | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| CN-113166639-A | Compounds for electronic devices | 默克专利有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020125403-A1 | PHARMACEUTICAL COMPOSITION | 江苏先声药业有限公司 | 2020-06-25 | — | — | WO | disclosed |
| CN-110325534-A | Substituted imidazoquinolines as NLRP3 modulators | 先天肿瘤免疫公司 | 2019-10-11 | — | — | CN | disclosed |
| EP-3510034-A1 | SUBSTITUTED IMIDAZO-QUINOLINES AS NLRP3 MODULATORS | Innate Tumor Immunity, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| WO-2018152396-A1 | SUBSTITUTED IMIDAZO-QUINOLINES AS NLRP3 MODULATORS | INNATE TUMOR IMMUNITY, INC. (US) | 2018-08-23 | — | — | WO | disclosed |
| CN-108250142-A | Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity | 维尔斯达医疗公司 | 2018-07-06 | — | — | CN | disclosed |
| EP-3331581-A1 | MECHANOPHORIC MEDICAL PRODUCT | Aesculap AG (DE) | 2018-06-13 | — | — | EP | disclosed |
| CN-108137586-A | novel imidazo [4,5-c ] quinoline and imidazo [4,5-c ] [1,5] naphthyridine derivatives as L RRK2 inhibitors | 辉瑞大药厂 | 2018-06-08 | — | — | CN | disclosed |
| CN-104968200-B | Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity | 维尔斯达医疗公司 | 2018-03-06 | — | — | CN | disclosed |
| WO-2016186453-A1 | QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS | KAINOS MEDICINE, INC. (KR) | 2016-11-24 | — | — | WO | disclosed |
| CN-104968200-A | Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity | WELLSTAT THERAPEUTICS CORP | 2015-10-07 | — | — | CN | disclosed |
| CN-103038217-A | Novel microbiocidal dioxime ether derivatives | SYNGENTA PARTICIPATIONS AG | 2013-04-10 | — | — | CN | disclosed |
| CN-102592040-A | Drug discovery method | KEDDEM BIO SCIENCE LTD | 2012-07-18 | — | — | CN | disclosed |
| CN-101410114-B | A3 adenosine receptor allosteric modulators | US GOV HEALTH & HUMAN SERV (US) | 2012-07-04 | — | — | CN | disclosed |
| US-20110178106-A1 | 5-QUINOLINONE AND IMIDAZOPYRIDINE COMPOUNDS AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE OFFICE OF COMMERCIALIZ (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178106-A1 | 5-QUINOLINONE AND IMIDAZOPYRIDINE COMPOUNDS AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE OFFICE OF COMMERCIALIZ (US) | 2011-07-21 | — | — | US | disclosed |
| CN-102088852-A | 5-quinolinone and imidazopyridine compounds and use thereof | SOUTHERN RES INST | 2011-06-08 | — | — | CN | disclosed |
| CN-102088852-A | 5-quinolinone and imidazopyridine compounds and use thereof | SOUTHERN RES INST | 2011-06-08 | — | — | CN | disclosed |
| CN-102088852-A | 5-quinolinone and imidazopyridine compounds and use thereof | SOUTHERN RES INST | 2011-06-08 | — | — | CN | disclosed |
| EP-2312948-A1 | 5-QUINOLINONE AND IMIDAZOPYRIDINE COMPOUNDS AND USE THEREOF | Southern Research Institute (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-2312948-A1 | 5-QUINOLINONE AND IMIDAZOPYRIDINE COMPOUNDS AND USE THEREOF | Southern Research Institute (US) | 2011-04-27 | — | — | EP | disclosed |
| WO-2010006251-A1 | 5-QUINOLINONE AND IMIDAZOPYRIDINE COMPOUNDS AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010006251-A1 | 5-QUINOLINONE AND IMIDAZOPYRIDINE COMPOUNDS AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2010-01-14 | — | — | WO | disclosed |
| EP-2125813-A2 | COMPOUNDS | Glaxo Group Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| EP-1819676-A4 | 5-PHENYL-5,6,7,8-HYDROQUINOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | disclosed |
| CN-101410114-A | A3 adenosine receptor allosteric modulators | US GOV HEALTH & HUMAN SERV (US) | 2009-04-15 | — | — | CN | disclosed |
| CN-100475207-C | 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2009-04-08 | — | — | CN | disclosed |
| WO-2008116815-A2 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| US-20080009518-A1 | 5-Phenyl-5,6,7,8-Hydroquinoline Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-01-10 | — | — | US | disclosed |
| EP-1819676-A2 | 5-PHENYL-5,6,7,8-HYDROQUINOLINE TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2007026371-A2 | PROCESS FOR PREPARING TRANDOLAPRIL AND INTERMEDIATES THEREOF | WOCKHARDT LIMITED (IN) | 2007-03-08 | — | — | WO | disclosed |
| CN-1914203-A | Sulfone substituted imidazo ring ethers | 3M INNOVATIVE PROPERTIES CO (US) | 2007-02-14 | — | — | CN | disclosed |
| EP-1694674-A2 | SULFONE SUBSTITUTED IMIDAZO RING ETHERS | 3M Innovative Properties Company (US) | 2006-08-30 | — | — | EP | disclosed |
| EP-1692138-A1 | PYRANO-QUINOLINES, PYRANO-QUINOLINONES, COMBINATIONS THEREOF, PHOTOCHROMIC COMPOSITIONS AND ARTICLES | TRANSITIONS OPTICAL, INC. (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2006060344-A2 | 5-PHENYL-5,6,7,8-HYDROQUINOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| CN-1747953-A | Aryl / hetaryl substituted imidazoquinolines. | 3M INNOVATIVE PROPERTIES CO (US) | 2006-03-15 | — | — | CN | disclosed |
| WO-2005123080-A2 | NITROGEN-CONTAINING HETEROCYCLYL SUBSTITUTED IMIDAZOQUINOLINES AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005076783-A2 | SULFONE SUBSTITUTED IMIDAZO RING ETHERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-08-25 | — | — | WO | disclosed |
| CN-1655788-A | 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2005-08-17 | — | — | CN | disclosed |
| WO-2005061514-A1 | PYRANO-QUINOLINES, PYRANO-QUINOLINONES, COMBINATIONS THEREOF, PHOTOCHROMIC COMPOSITIONS AND ARTICLES | TRANSITIONS OPTICAL, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| CN-1422269-A | 1H-imidazopyridine derivatives | HOKURIKU PHARMACEUTICAL (JP) | 2003-06-04 | — | — | CN | disclosed |
| CN-1093860-C | Pyridazino [4, 5-b ] quinoline 5-oxide derivatives, their preparation and their use as glycine antagonists | MERZ & CO GMBH & CO (DE) | 2002-11-06 | — | — | CN | disclosed |
| EP-1194429-A1 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-10 | — | — | EP | disclosed |
| EP-0894796-B1 | Imidazolines substituted with a heterocyclic ring as alpha-2 antagonists | ADIR (FR) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000078768-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | disclosed |
| EP-1040097-A1 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2000-10-04 | — | — | EP | disclosed |
| CN-1228778-A | Pyridazino [4,5-b]-quinoline 5-oxide derivatives, their preparation and their use as glycine antagonists | MERZ & CO GMBH & CO (DE) | 1999-09-15 | — | — | CN | disclosed |
| WO-1999031059-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0894796-A1 | Imidazolines substituted with a heterocyclic ring as alpha-2 antagonists | ADIR ET COMPAGNIE (FR) | 1999-02-03 | — | — | EP | disclosed |
| EP-0888347-A1 | PHARMACEUTICALLY USEFUL COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 1999-01-07 | — | — | EP | disclosed |
| EP-0489379-B1 | 5-amino-5,6,7,8-tetrahydroquinolines and related compounds, a process for their preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (US) | 1998-07-15 | — | — | EP | disclosed |
| WO-1997034893-A1 | PHARMACEUTICALLY USEFUL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1997-09-25 | — | — | WO | disclosed |
| US-5310914-A | Imination, reduction | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-05-10 | — | — | US | disclosed |
| US-5216164-A | Used for relieving memory dysfunction such as Alzheimer's disease | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-06-01 | — | — | US | disclosed |
| EP-0489379-A1 | 5-amino-5,6,7,8-tetrahydroquinolines and related compounds, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-06-10 | — | — | EP | disclosed |
| US-5110815-A | Alzheimer's disease | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1992-05-05 | — | — | US | disclosed |
| US-3978079-A | DIPHTHALIMIDO, DISUCCINIMIDO AND DIMALEIMIDO OXALATES | AMERICAN CYANAMID COMPANY (US) | 1976-08-31 | — | — | US | disclosed |
| US-3970660-A | BIS(1,2-DIHYDRO-2-OXO-1-PYRIDYL) GLYOXAL | AMERICAN CYANAMID COMPANY (US) | 1976-07-20 | — | — | US | disclosed |
| US-3970660-A | BIS(1,2-DIHYDRO-2-OXO-1-PYRIDYL) GLYOXAL | AMERICAN CYANAMID COMPANY (US) | 1976-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178106-A1 | 5-QUINOLINONE AND IMIDAZOPYRIDINE COMPOUNDS AND USE THEREOF | ABCC5, ABCC1, ABCB1 | AURKA 1267/4885KDR 4240/4885CDK2 1589/4885 |
| US-20080009518-A1 | 5-Phenyl-5,6,7,8-Hydroquinoline Tachykinin Receptor Antagonists | TACR1, HTR5A, TACR2 | AURKA 1495/4885KDR 1960/4885CDK2 872/4885 |
| US-20220133740-A1 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | WNT3A, WNT1, WNT3 | AURKA 1721/4885KDR 3862/4885CDK2 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.